116 CHAPTER 6 sub-study: 16 in the multidisciplinary rehabilitation group and 11 in the usual care group (see Table 1 for participant characteristics). NA patients were recruited through the Radboud University Medical Center’s Neuromuscular Center between March 1st 2018 and March 16th 2020 and were included if they met the following criteria: presenting with clearly lateralized symptoms of the right upper extremity; exhibiting explicit coordinative motor dysfunction (scapular dyskinesia); no longer in the acute inflammatory phase (>8 weeks after attack onset); no prior participation in the multidisciplinary rehabilitation program; no relevant comorbidities; ≥ 18 years of age; right hand dominance (score of > +40 on the Edinburgh Handedness Inventory). 46 Patients were excluded from further participation if they experienced a recurrent NA attack during the treatment period. All MRI assessments took place between April 1st 2018 and August 1st 2020. Procedures Patients were informed about the procedures of the study and gave written informed consent prior to their participation, in accordance with the declaration of Helsinki. All patients underwent a baseline assessment, followed by a 17-week treatment period and a follow-up assessment. Patients were first randomized into either the multidisciplinary rehabilitation group or usual care group in a 1:1 ratio, considering age and sex (see Lustenhouwer et al. 124 for details), after baseline assessment. Patients in Table 1 Participant characteristics Participant characteristics of the patients that were included in the final analyses. Mean ± standard deviation are displayed for all measures. NA=neuralgic amyotrophy; SRQ-DLV=Shoulder Rating Questionnaire, Dutch Language Version; VAS=Visual Analogue Scale. a=significant difference between groups p < 0.05; b=significant difference between time points (within group) p ≤ 0.01.